Applied dna partners with genxys health care systems to deploy clinical decision support system for pharmacogenetic (pgx) testing

Partnership will aid physicians in precision prescribing decisions based on applied dna's tr8™ pharmacogenomic (pgx) test stony brook, ny / accesswire / june 18, 2024 / applied dna sciences, inc. (nasdaq:apdn) (applied dna), a global leader in pcr-based dna technologies, today announced that its molecular diagnostics subsidiary, applied dna clinical labs, llc (adcl), will utilize the genxys health care systems (genxys) suite of clinical decision support software for interpretation and reporting of adcl's new york state department of health-approved tr8™ pharmacogenomic (tr8 pgx) test. the partnership is designed to improve patient outcomes and reduce healthcare costs through a data-driven approach that relates an individual's genetic factors to potential responses to prescription drugs.
DNA Ratings Summary
DNA Quant Ranking